Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1F | P30939 | 6/20 | 0.68 |
| ▸ | HTR1D | P28221 | 4/20 | 0.65 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.65 |
| ▸ | DRD5 | P21918 | 1/20 | 0.65 |
| ▸ | HTR1E | P28566 | 1/20 | 0.65 |
| ▸ | HTR7 | P34969 | 1/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.65 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 4/20 | 0.51 |
| ▸ | HTR1B | P28222 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 5/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.45 |
| ▸ | WNT1 | P04628 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | KDM4A | O75164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2539945 | 0.97 | HTR1F (0.68) | HTR1FHTR1DCHRM5DRD5HTR1E | |
| SCHEMBL2535443 | 0.96 | HTR1F (0.67) | HTR1FHTR1DCHRM5DRD5HTR1E | |
| SCHEMBL2537303 | 0.95 | HTR1F (0.71) | HTR1FHTR1DCHRM5DRD5HTR1E | |
| SCHEMBL2540244 | 0.84 | HTR1F (0.81) | HTR1FHTR1DCHRM5DRD5HTR1E | |
| SCHEMBL22861503 | 0.84 | HTR1F (0.67) | HTR1FHTR1DCHRM5DRD5HTR1E | |
| SCHEMBL29581460 | 0.84 | HTR1F (0.67) | HTR1FHTR1DCHRM5DRD5HTR1E | |
| SCHEMBL30908975 | 0.83 | HTR1F (0.72) | HTR1FHTR1DCHRM5DRD5HTR1E | |
| SCHEMBL2537883 | 0.83 | HTR1F (0.72) | HTR1FHTR1DCHRM5DRD5HTR1E | |
| Hydrochloric Acid SCHEMBL2535877 | 0.83 | HTR1F (0.79) | HTR1FHTR1DCHRM5DRD5HTR1E | |
| SCHEMBL2535880 | 0.82 | HTR1F (0.78) | HTR1FHTR1DCHRM5DRD5HTR1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ LP (CA) | 2026-05-07 | — | — | US | disclosed |
| WO-2024073845-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ, LIMITED PARTNERSHIP (CA) | 2024-04-11 | — | — | WO | disclosed |
| US-20170044136-A1 | Pyridinoylpiperidines As 5-HT1F Agonists | LILLY CO ELI (US) | 2017-02-16 | — | — | US | disclosed |
| US-20170044136-A1 | Pyridinoylpiperidines As 5-HT1F Agonists | LILLY CO ELI (US) | 2017-02-16 | — | — | US | disclosed |
| US-20150376178-A1 | Pyridinoylpiperidines As 5-HT1F Agonists | ELI LILLY AND COMPANY | 2015-12-31 | — | — | US | disclosed |
| US-20150376178-A1 | Pyridinoylpiperidines As 5-HT1F Agonists | ELI LILLY AND COMPANY | 2015-12-31 | — | — | US | disclosed |
| US-8748459-B2 | Pyridinoylpiperidines as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120329820-A1 | Pyridinoylpiperidines As 5-HT1F Agonists | ELI LILLY AND COMPANY (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120329820-A1 | Pyridinoylpiperidines As 5-HT1F Agonists | ELI LILLY AND COMPANY (US) | 2012-12-27 | — | — | US | disclosed |
| US-8044207-B2 | Pyridinoylpiperidines as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2011-10-25 | — | — | US | disclosed |
| US-20090209563-A1 | Pyridinoylpiperidines as 5-HT1F agonists | ELI LILLY AND COMPANY | 2009-08-20 | — | — | US | disclosed |
| US-20090209563-A1 | Pyridinoylpiperidines as 5-HT1F agonists | ELI LILLY AND COMPANY | 2009-08-20 | — | — | US | disclosed |
| US-20080300407-A1 | Pyridinoylpiperidines as 5-HT1F agonists | ELI LILLY AND COMPANY (IN) | 2008-12-04 | — | — | US | disclosed |
| US-20080300407-A1 | Pyridinoylpiperidines as 5-HT1F agonists | ELI LILLY AND COMPANY (IN) | 2008-12-04 | — | — | US | disclosed |
| US-20080300407-A1 | Pyridinoylpiperidines as 5-HT1F agonists | ELI LILLY AND COMPANY (IN) | 2008-12-04 | — | — | US | disclosed |
| US-7423050-B2 | Pyridinoylpiperidines as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423050-B2 | Pyridinoylpiperidines as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423050-B2 | Pyridinoylpiperidines as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2008-09-09 | — | — | US | disclosed |
| EP-1492786-B1 | PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS | LILLY CO ELI (US) | 2006-10-04 | — | — | EP | disclosed |
| US-20050222206-A1 | Pyridinoylpiperidines as 5-ht1f agonists | ELI LILLY AND COMPANY | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300407-A1 | Pyridinoylpiperidines as 5-HT1F agonists | HTR1F, HTR1A, HTR1E | HTR1F 1/4885HTR1D 4/4885CHRM5 268/4885 |
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | HTR1F, HTR1A, HTR1D | HTR1F 1/4885HTR1D 3/4885CHRM5 816/4885 |
| US-20120329820-A1 | Pyridinoylpiperidines As 5-HT1F Agonists | HTR1F, HTR1A, HTR1E | HTR1F 1/4885HTR1D 4/4885CHRM5 239/4885 |
| US-20170044136-A1 | Pyridinoylpiperidines As 5-HT1F Agonists | HTR1F, HTR1A, HTR1E | HTR1F 1/4885HTR1D 4/4885CHRM5 239/4885 |
| US-20050222206-A1 | Pyridinoylpiperidines as 5-ht1f agonists | HTR1F, HTR1A, HTR1E | HTR1F 1/4885HTR1D 4/4885CHRM5 239/4885 |
| US-20150376178-A1 | Pyridinoylpiperidines As 5-HT1F Agonists | HTR1F, HTR1A, HTR1E | HTR1F 1/4885HTR1D 4/4885CHRM5 239/4885 |
| US-20090209563-A1 | Pyridinoylpiperidines as 5-HT1F agonists | HTR1F, HTR1A, HTR1E | HTR1F 1/4885HTR1D 4/4885CHRM5 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.